Mon, November 13, 2023
Sun, November 12, 2023
Fri, November 10, 2023
Thu, November 9, 2023

Tommie Reerink Maintained (ATRA) at Strong Sell with Decreased Target to $13 on, Nov 10th, 2023


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. ith-decreased-target-to-13-on-nov-10th-2023.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Tommie Reerink of Goldman Sachs, Maintained "Atara Biotherapeutics, Inc." (ATRA) at Strong Sell with Decreased Target from $75 to $13 on, Nov 10th, 2023.

Tommie has made no other calls on ATRA in the last 4 months.



There are 5 other peers that have a rating on ATRA. Out of the 5 peers that are also analyzing ATRA, 3 agree with Tommie's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Michael DiFiore of "Evercore ISI Group" Downgraded from Buy to Hold on, Thursday, November 9th, 2023
  • Robert Burns of "HC Wainwright & Co." Downgraded from Strong Buy to Hold on, Thursday, November 9th, 2023
  • Salim Syed of "Mizuho" Downgraded from Strong Buy to Hold and Decreased Target to $25 on, Thursday, November 9th, 2023


These are the ratings of the 2 analyists that currently disagree with Tommie


  • Yigal Nochomovitz of "Citigroup" Maintained at Strong Sell with Decreased Target to $35 on, Monday, August 21st, 2023
  • Anthony Butler of "EF Hutton" Reiterated at Strong Buy and Held Target at $625 on, Wednesday, August 9th, 2023

Publication Contributing Sources